Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 17/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23925668 | 1.00 | EGLN2 (0.38) | EGLN2HTTMEN1ALDH1A1GAA | |
| SCHEMBL25616199 | 0.90 | EGLN2 (0.39) | EGLN2HTTMEN1ALDH1A1GAA | |
| SCHEMBL4819496 | 0.89 | MAPK1 (0.34) | MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL25616232 | 0.89 | EGLN2 (0.45) | EGLN2 | |
| SCHEMBL29974295 | 0.89 | EGLN2 (0.45) | EGLN2 | |
| SCHEMBL23944198 | 0.88 | EGLN2 (0.39) | EGLN2HTTMEN1ALDH1A1GAA | |
| SCHEMBL23944197 | 0.88 | EGLN2 (0.40) | EGLN2HTTMEN1ALDH1A1GAA | |
| SCHEMBL25616206 | 0.88 | EGLN2 (0.40) | EGLN2HTTMEN1ALDH1A1GAA | |
| SCHEMBL23925449 | 0.79 | EGLN2 (0.46) | EGLN2 | |
| SCHEMBL23925452 | 0.79 | EGLN2 (0.46) | EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167121-A1 | SUBSTITUTED {1,2,4,} TRIAZOLO{1,5-A} PYRIMIDINE COMPOUNDS AND USE IN STABILIZING MICROTUBULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-06-01 | — | — | US | disclosed |
| EP-4136089-A1 | SUBSTITUTED {1,2,4,} TRIAZOLO{1,5-A} PYRIMIDINE COMPOUNDS AND USE IN STABILIZING MICROTUBULES | The Trustees of The University of Pennsylvania (US) | 2023-02-22 | — | — | EP | disclosed |
| WO-2021211408-A1 | SUBSTITUTED {1,2,4,} TRIAZOLO{1,5-A} PYRIMIDINE COMPOUNDS AND USE IN STABILIZING MICROTUBULES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167121-A1 | SUBSTITUTED {1,2,4,} TRIAZOLO{1,5-A} PYRIMIDINE COMPOUNDS AND USE IN STABILIZING MICROTUBULES | MAPT, TUBA4A, MAP4 | EGLN2 4728/4885HTT 118/4885MEN1 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.